Biotech Values

[iwfal]

The article has too many flaws to enumerate. I tweeted about one them: The model's assumption that a typical drug experiences only six years of freedom from generic competition.

Yeah - I picked up on that one and, being the math geek that I am, I instantly saw that there was no way the revenue/EBIT/R&D curves extrapolate out to the linear decline predicted. Then, as you note, once examined the other flaws become obvious. Essentially the article was click-bait - but I found it interesting how many people found it worthy of non-critical comment. And ultimately part of the reason I posted a critique is because so many seemed to accept large pieces of it.